Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Black Diamond Reports $10.0 Million Q3 Loss and Updated Silevertinib Data

None

Black Diamond Therapeutics (BDTX) reported a third-quarter 2026 net loss of $10.0 million, or $0.17 per basic and diluted share, compared with a $8.5 million loss a year earlier. The company ended the quarter with approximately $102.0 million in cash, cash equivalents and investments.

The company reported updated Phase 2 silevertinib data in frontline EGFR non-classical mutation NSCLC and said FDA feedback supports its planned registrational Phase 3 program, which it expects could begin in the second quarter of 2027.

  • Phase 2 intention-to-treat population of 43 patients recorded 60% ORR, 93% disease control rate and median progression-free survival of 15.0 months.
  • Among 16 patients with untreated brain metastases, CNS objective response rate was 86% in seven RANO-BM evaluable patients.
  • Research and development expense was $7.0 million, while general and administrative expense was $5.1 million.
  • Black Diamond expects its cash position to fund operations into the second half of 2028.
  • The planned Phase 3 trial would enroll 300 patients with EGFR-NCMs and untreated brain metastases.

$BDTX Hedge Fund Activity

We have seen 66 institutional investors add shares of $BDTX stock to their portfolio, and 62 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles